Shanghai Pharmaceuticals Holding (02607) released its annual performance for 2025, with a net profit attributable to shareholders of 5.725 billion yuan, an increase of 25.74% year-on-year.

Shanghai Pharmaceuticals Holding (02607) released its performance for the year 2025, with operating income reaching 283.58 billion yuan (RMB, the same below), a year-on-year increase of 3.03%. Among them, sales revenue from the pharmaceutical industry reached 24.522 billion yuan, an increase of 3.33% year-on-year; sales revenue from pharmaceutical commerce reached 259.058 billion yuan, an increase of 3.00% year-on-year. The net profit attributable to shareholders of the listed company was 5.725 billion yuan, an increase of 25.74% year-on-year. The year-on-year increase in net profit attributable to shareholders of the listed company was mainly due to a one-time special income resulting from the change in accounting treatment of joint ventures with Hutchison Whampoa from equity method to subsidiary method. Excluding the above-mentioned one-time special gains and losses, the net profit attributable to equity holders was 4.721 billion yuan, a decrease of 5.56% year-on-year. During the reporting period, the industrial sector contributed profits of 2.039 billion yuan, while the commercial sector contributed profits of 3.457 billion yuan, with major associated companies contributing profits of 325 million yuan. In terms of new drug research and development, the innovative drug malic acid sartogrel tablets (Class 1) was successfully approved for listing, providing a new treatment option for over 300 million primary hypertension patients in China, becoming one of the company's iconic achievements in recent years. The highly humanized global innovative anti-CD20 antibody drug-B001 injection for the treatment of optic nerve sheath myelinopathy spectrum disorders has completed key research endpoint analysis, and the traditional Chinese medicine Class 1.1 new drug Shenqi Shenrong Pill for the treatment of cervical spondylosis with spinal type has completed the Outgroup of all cases in Phase III clinical trials. The traditional medicine Class 1 new drug SHPL-49 injection for the treatment of acute ischemic stroke and the SRD4610 (Porlia Cocos Mycelium Granules) for the treatment of amyotrophic lateral sclerosis are steadily progressing in Phase III clinical trials, with pipeline staggered optimization; positive progress has been made in the new track of cell and gene therapy, and it is expected to inject new vitality into innovation development in the future. In terms of building an innovative ecosystem, the company adheres to the aggregation of "production, learning, research, medical, and capital" resources and accelerates the construction of "one hospital and four institutes" by strengthening the internal construction of peptide, macromolecule, small molecule, nucleic acid, and other technology platforms. Through in-depth cooperation with national key laboratories, Shanghai Jiaotong University, and other research institutes, the company continuously consolidates the internal and external coordinated research and development management system; at the same time, the company relies on Shanghai's cutting-edge attractiveness to attract high-quality enterprises and institutions to settle in, bridging in equity financing and policy support, and continuously empowering to jointly create an open and vibrant innovative ecosystem.